Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With Locally Advanced or Metad or Metastatic Urothelial Cancer

NCT03359239 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT03359239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03359239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With Locally Advanced or Metad or Metastatic Urothelial Cancer
Lead sponsor
Matthew Galsky
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2019
Completion date
October 12, 2021
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial/bladder cancer, nos